Laryngeal neoplasm
disease diseaseOn this page
Also known as laryngeal tumorlaryngeal tumourlarynx neoplasmlarynx neoplasm (disease)larynx tumorlarynx tumourneoplasm of larynxneoplasm of the larynxtumor of larynxtumor of the larynxtumour of larynxtumour of the larynx
Summary
Laryngeal neoplasm (MONDO:0021071) is a cancer (an umbrella term covering 6 Mondo subtypes) and 36 clinical trials. Top therapeutic interventions include cobimetinib, dabrafenib, and trametinib. A subtype of laryngeal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 36
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | laryngeal neoplasm |
| Mondo ID | MONDO:0021071 |
| EFO | EFO:0003817 |
| MeSH | D007822 |
| NCIT | C3156 |
| SNOMED CT | 126692004 |
| UMLS | C0023055 |
| MedGen | 7271 |
| Anatomy (UBERON) | UBERON:0001737 |
| Is cancer (heuristic) | yes |
Also known as: laryngeal neoplasm · laryngeal tumor · laryngeal tumour · larynx neoplasm · larynx neoplasm (disease) · larynx tumor · larynx tumour · neoplasm of larynx · neoplasm of the larynx · tumor of larynx · tumor of the larynx · tumour of larynx · tumour of the larynx
Disease family
This is a subtype of laryngeal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › respiratory system disorder › upper respiratory tract disorder › laryngeal disorder › laryngeal neoplasm
Related subtypes (19): spasmodic dystonia, laryngostenosis, laryngitis, laryngeal abductor paralysis, congenital laryngomalacia, larynx atresia, congenital laryngeal web, H syndrome, primary laryngeal lymphangioma, congenital laryngeal palsy, congenital subglottic stenosis, congenital laryngeal cyst, laryngocele, laryngeal diphtheria, laryngeal granuloma, polyp of vocal cord, voice disorders, acquired laryngomalacia, idiopathic subglottic stenosis
Subtypes (6): subglottis neoplasm, larynx cancer, glottis neoplasm, benign laryngeal neoplasm, supraglottis neoplasm, laryngeal neuroendocrine neoplasm
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
4 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Status |
|---|---|
| Carboplatin | Approved (phase 3) |
| Cisplatin | Approved (phase 3) |
| Fluorouracil | Approved (phase 3) |
| Hydroxyurea | Approved (phase 3) |
5 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| 5-FLUORONICOTINIC ACID | Phase 3 |
| Cefazolin | Phase 3 |
| Cetuximab | Phase 2 |
| Isosorbide | Phase 2 |
| Oxygen | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 36.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 21 |
| PHASE2 | 8 |
| PHASE2/PHASE3 | 2 |
| PHASE1 | 2 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05768178 | PHASE2/PHASE3 | RECRUITING | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. |
| NCT07440290 | PHASE2/PHASE3 | NOT_YET_RECRUITING | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. |
| NCT00128817 | PHASE3 | TERMINATED | Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers |
| NCT06137378 | PHASE2 | RECRUITING | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] |
| NCT06554028 | PHASE2 | NOT_YET_RECRUITING | Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer |
| NCT07400094 | PHASE2 | NOT_YET_RECRUITING | Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC |
| NCT00127465 | PHASE1/PHASE2 | COMPLETED | Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants |
| NCT00721799 | PHASE2 | COMPLETED | F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients |
| NCT00941135 | PHASE2 | TERMINATED | Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab |
| NCT01216020 | PHASE2 | TERMINATED | Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer |
| NCT02633540 | PHASE2 | TERMINATED | Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function |
| NCT04995120 | PHASE2 | UNKNOWN | Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma |
| NCT00396617 | PHASE1 | UNKNOWN | Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy |
| NCT00576134 | PHASE1 | COMPLETED | The Objective is to Respond to Patients’ Needs in the Field of Larynx Replacement |
| NCT00965003 | EARLY_PHASE1 | TERMINATED | MRI Laryngeal Imaging With a Surface Coil |
| NCT07391345 | Not specified | RECRUITING | Precision Medicine: MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) for Early-Stage Glottic Laryngeal Cancer |
| NCT00001603 | Not specified | COMPLETED | The Effects of Upper Airway and Digestive Tract Tumors on the Immune System |
| NCT00534729 | Not specified | COMPLETED | Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA |
| NCT00721539 | Not specified | TERMINATED | Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract |
| NCT01104714 | Not specified | COMPLETED | Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers |
| NCT01171235 | Not specified | UNKNOWN | Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma |
| NCT01257633 | Not specified | COMPLETED | Surgical Treatment of Early Stage Glotto-supraglottic Laryngeal Cancer Via Transoral Resection With Robotic Assistance |
| NCT02430675 | Not specified | COMPLETED | Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms |
| NCT02628496 | Not specified | WITHDRAWN | Confocal Laser Microlaryngoscopy (CLMx) |
| NCT02672904 | Not specified | UNKNOWN | KTP vs CO2 Laser for the Treatment of Laryngeal Carcinoma |
| NCT03010813 | Not specified | COMPLETED | A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery |
| NCT03214835 | Not specified | WITHDRAWN | CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions |
| NCT03392220 | Not specified | UNKNOWN | A Multicenter, Randomized, Case-control Study of Unilateral vs Bilateral Neck Dissection for cN0 Supraglottic Laryngeal Cancer |
| NCT03585075 | Not specified | COMPLETED | Characterization of the Autofluorescence of Healthy and Pathological Tissues of Vocal Cords |
| NCT03942380 | Not specified | UNKNOWN | Cell-free Tumor DNA in Head and Neck Cancer Patients |
| NCT04110249 | Not specified | TERMINATED | Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer |
| NCT04278638 | Not specified | UNKNOWN | IORT in Local Advanced Laryngocarcinoma |
| NCT05346237 | Not specified | COMPLETED | Validation and Cross-cultural Adaptation of Croatian SECEL Questionnaire |
| NCT05406024 | Not specified | COMPLETED | Feasibility Study CORPPS |
| NCT06227039 | Not specified | UNKNOWN | Patient Augmented Reality and Vibratory Array Otorhinolaryngology Procedures |
| NCT06852651 | Not specified | COMPLETED | The Efficacy of Superficial Cervical Block Application in Postoperative Analgesia Management in Patients Undergoing Total Laryngectomy and Bilateral Neck Dissection |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| COBIMETINIB | 4 | 1 |
| DABRAFENIB | 4 | 1 |
| TRAMETINIB | 4 | 1 |
| VEMURAFENIB | 4 | 1 |
| CHEMBL3415553 | 0 | 1 |
| CHEMBL4209555 | 0 | 1 |
| CHEMBL4538425 | 0 | 1 |
| CHEMBL5433950 | 0 | 1 |
| PLX-4720 | 0 | 1 |
Related Atlas pages
- Drugs: Cobimetinib, Dabrafenib, Trametinib, Vemurafenib